News on immunohistochemistry and other tissue-based testing methods.
The company raised $3.2 million in seed financing, which will go toward development of its platform and deployment of its flagship technology called VIPER.
The funding will be directed at conducting clinical trials for its technology based on activity sensors to detect human diseases and monitor drug responses.
In some instances, Ventana said, a retrospective review and retesting of clinical cases using the affected dispensers would be necessary.
Quest also announced a partnership to provide supply chain expertise and run lab reference testing for Regional Medical Center Health System.
The firm will use the funds to expand deployment of its digital pathology software and accelerate use of artificial intelligence applications.
